IL163731A0 - Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid - Google Patents
Administration of acetylcholinesterase inhibitors to the cerebral spinal fluidInfo
- Publication number
- IL163731A0 IL163731A0 IL16373103A IL16373103A IL163731A0 IL 163731 A0 IL163731 A0 IL 163731A0 IL 16373103 A IL16373103 A IL 16373103A IL 16373103 A IL16373103 A IL 16373103A IL 163731 A0 IL163731 A0 IL 163731A0
- Authority
- IL
- Israel
- Prior art keywords
- administration
- spinal fluid
- cerebral spinal
- acetylcholinesterase inhibitors
- acetylcholinesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38212202P | 2002-05-21 | 2002-05-21 | |
PCT/US2003/015653 WO2004002402A2 (en) | 2002-05-21 | 2003-05-19 | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163731A0 true IL163731A0 (en) | 2005-12-18 |
Family
ID=30000415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16373103A IL163731A0 (en) | 2002-05-21 | 2003-05-19 | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
Country Status (9)
Country | Link |
---|---|
US (1) | US20030225031A1 (xx) |
EP (1) | EP1505971A2 (xx) |
JP (1) | JP2005532372A (xx) |
AU (1) | AU2003269874A1 (xx) |
CA (1) | CA2482161A1 (xx) |
IL (1) | IL163731A0 (xx) |
NZ (1) | NZ535192A (xx) |
WO (1) | WO2004002402A2 (xx) |
ZA (1) | ZA200407420B (xx) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
EP1513853A2 (en) * | 2002-05-24 | 2005-03-16 | Neopharm, Inc. | Cardiolipin compositions, methods of preparation and use |
EA200401565A1 (ru) * | 2002-05-24 | 2005-04-28 | Неофарм, Инк. | Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты) |
US20050277611A1 (en) * | 2002-10-16 | 2005-12-15 | Neopharm, Inc. | Cationic cardiolipin analoges and its use thereof |
US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
WO2005013906A2 (en) * | 2003-08-08 | 2005-02-17 | Sri International | pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT |
DE10340740A1 (de) * | 2003-09-04 | 2005-03-31 | Degussa Food Ingredients Gmbh | Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis |
AT500143A1 (de) * | 2004-04-22 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung |
WO2006013546A2 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Process for the preparation of pure galantamine |
US20060194723A1 (en) * | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
WO2006130726A2 (en) * | 2005-06-01 | 2006-12-07 | Teva Pharmaceutical Industries, Ltd. | Use of ladostigil for the treatment of multiple sclerosis |
CU23317A1 (es) * | 2005-07-22 | 2008-10-22 | Ct De Investigacia N Y Desarro | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
PL1933809T3 (pl) * | 2005-10-11 | 2012-09-28 | Yissum Research Development Company Of The Hebrew Univ Of Jerusalem | Kompozycje do dostarczania donosowego |
CN1961879B (zh) * | 2005-11-09 | 2011-11-30 | 上海医药工业研究院 | 组成石杉碱甲鼻用原位凝胶喷雾剂的药物组合物、其制备方法及用途 |
WO2007078879A2 (en) * | 2005-12-21 | 2007-07-12 | Vaxinnate Corporation | Lipopeptide compositions and methods of use thereof |
WO2007086493A1 (ja) * | 2006-01-27 | 2007-08-02 | Asahi Kasei Pharma Corporation | 経鼻投与用薬剤 |
US20080319083A1 (en) * | 2006-01-27 | 2008-12-25 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
JP5122791B2 (ja) * | 2006-09-22 | 2013-01-16 | 石川金属株式会社 | はんだ付け用フラックスおよびソルダペーストとヤニ入りはんだ |
US8969402B2 (en) | 2006-11-15 | 2015-03-03 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
DE102006056783A1 (de) * | 2006-12-01 | 2008-06-05 | Lts Lohmann Therapie-Systeme Ag | Zubereitung zur transdermalen Verabreichung von Galanthamin |
WO2008066179A1 (fr) * | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Préparation d'absorption percutanée |
US20080131490A1 (en) * | 2006-12-01 | 2008-06-05 | Akinori Hanatani | Stabilized donepezil-containing patch preparation |
US20100016362A1 (en) * | 2007-01-19 | 2010-01-21 | Eisai R & D Management Co., Ltd. | Stabilized pharmaceutical composition containing donepezil, process of producing same and method for stabilization |
EP2170399A1 (en) * | 2007-06-05 | 2010-04-07 | Synthon B.V. | Intranasal administration of asenapine and pharmaceutical compositions therefor |
BRPI0913229A2 (pt) * | 2008-05-30 | 2016-01-19 | Nitto Denko Corp | preparação adesiva contendo donepezil e embalagem da mesma |
WO2009145269A1 (ja) * | 2008-05-30 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 経皮吸収製剤 |
AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
EP2649181B1 (en) | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
BR112013033488B8 (pt) * | 2011-06-27 | 2022-11-22 | Eisai R&D Man Co Ltd | Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit |
US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
AU2013312240A1 (en) * | 2012-09-10 | 2015-03-19 | Ophirex Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US9872865B2 (en) * | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
WO2015015498A1 (en) | 2013-07-31 | 2015-02-05 | Qbi Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
WO2015148480A1 (en) | 2014-03-25 | 2015-10-01 | Emicipi Llc | Treatment of rett syndrome |
EP2979688A1 (en) * | 2014-08-01 | 2016-02-03 | Britannia Pharmaceuticals Limited | Composition containing Apomorphine and a Divalent Metal Cation |
AU2015327762C1 (en) * | 2014-10-03 | 2020-10-22 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
MA40998A (fr) | 2014-11-21 | 2017-09-26 | Ophirex Inc | Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés |
US10123969B2 (en) | 2015-10-15 | 2018-11-13 | Wisconsin Alumni Research Foundation | Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid |
JPWO2018092765A1 (ja) * | 2016-11-15 | 2019-10-17 | 学校法人同志社 | 経鼻投与用医薬組成物 |
CN107375945B (zh) * | 2017-08-29 | 2020-10-13 | 沈阳药科大学 | 一种多奈哌齐环糊精包合物及含有此包合物的口服速溶膜剂 |
CN110507610A (zh) * | 2019-07-24 | 2019-11-29 | 西北农林科技大学 | 一种含有维生素d的纳米乳药物及其制备方法 |
US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
CU20200087A7 (es) | 2020-11-24 | 2022-07-08 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
CN114432495B (zh) * | 2021-12-09 | 2022-09-20 | 中国人民解放军空军军医大学 | 一种可促进内源性骨再生的生物材料及其制备方法和应用 |
CN115919767B (zh) * | 2022-10-13 | 2023-08-11 | 暨南大学 | 卡巴拉汀鼻喷雾剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993002999A1 (en) * | 1991-08-10 | 1993-02-18 | Hisamitsu Pharmaceutical Co., Inc. | Phenylalkanoic acid derivative, production thereof, and separation of optical isomers thereof |
SE9504537D0 (sv) * | 1995-12-19 | 1995-12-19 | Jan Hedner | Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet |
TW513409B (en) * | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
WO2001038547A2 (en) * | 1999-11-24 | 2001-05-31 | Mcs Micro Carrier Systems Gmbh | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
-
2003
- 2003-05-15 US US10/439,108 patent/US20030225031A1/en not_active Abandoned
- 2003-05-19 JP JP2004517563A patent/JP2005532372A/ja not_active Withdrawn
- 2003-05-19 IL IL16373103A patent/IL163731A0/xx unknown
- 2003-05-19 NZ NZ535192A patent/NZ535192A/en unknown
- 2003-05-19 EP EP03751761A patent/EP1505971A2/en not_active Withdrawn
- 2003-05-19 CA CA002482161A patent/CA2482161A1/en not_active Abandoned
- 2003-05-19 WO PCT/US2003/015653 patent/WO2004002402A2/en active Application Filing
- 2003-05-19 AU AU2003269874A patent/AU2003269874A1/en not_active Abandoned
-
2004
- 2004-09-15 ZA ZA200407420A patent/ZA200407420B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1505971A2 (en) | 2005-02-16 |
JP2005532372A (ja) | 2005-10-27 |
US20030225031A1 (en) | 2003-12-04 |
WO2004002402A2 (en) | 2004-01-08 |
NZ535192A (en) | 2006-05-26 |
CA2482161A1 (en) | 2004-01-08 |
ZA200407420B (en) | 2006-06-28 |
WO2004002402A3 (en) | 2004-10-07 |
AU2003269874A1 (en) | 2004-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL163731A0 (en) | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid | |
HK1215265A1 (zh) | α相關疾病的治療 | |
IL172621A0 (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
PL374700A1 (en) | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders | |
HK1089107A1 (en) | Delivery of therapeutic compounds to the brain and other tissues | |
SI1673104T2 (sl) | Dostava terapevtskih spojin možganom in drugim tkivom | |
EP1638605A4 (en) | DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE | |
AU2003286741A8 (en) | Methods and compositions for diagnosis and therapy of parkin-associated disorders | |
GB0305150D0 (en) | Use of therapeutic compounds | |
PL1740204T3 (pl) | Lecznicze zastosowanie alfa-mannozydazy | |
PT1487828E (pt) | Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias | |
IL172018A0 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
HUP0401641A3 (en) | Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors | |
AU2003247140A1 (en) | Delivering compounds to the brain by modifying properties of the bbb and cerebral circulation | |
AU2003289652A1 (en) | The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion | |
AU2002350832A1 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
EP1651956A4 (en) | MELKS AS MODIFIERS OF THE ACTION ACTION MECHANISM AND METHODS OF USE | |
IL175674A0 (en) | Method to improve the efficacy of therapeutic radiolabeled drugs | |
GB2410744B (en) | Kinase inhibitors for the treatment of disease | |
GB0201025D0 (en) | The treatment of degenerative diseases | |
AU4838301A (en) | Treatment of disorders relating to the serotonergic system | |
AU2003237524A1 (en) | Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders | |
HUP0402664A3 (en) | 2-indanylamino derivatives for the therapy of chronic pain | |
GB0312844D0 (en) | Use of compounds in medicine | |
GB0427124D0 (en) | Inhibitor of anticancer drug side effect |